Maller B, Bigness A, Moiño D, Greene J. Sweet's syndrome associated with hematological malignancies.
Leuk Res 2020;
99:106461. [PMID:
33099235 DOI:
10.1016/j.leukres.2020.106461]
[Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2020] [Revised: 10/09/2020] [Accepted: 10/12/2020] [Indexed: 11/17/2022]
Abstract
BACKGROUND
Sweet's syndrome, or acute febrile neutrophilic dermatosis, is often mistaken for a skin infection given its similar clinical presentation.
OBJECTIVE
To describe the clinical presentations and management of a rare dermatologic condition associated with hematological malignancies.
METHODS
Case series; Chart review of patients at Moffitt Cancer Center between 2017 and 2020.
RESULTS
The subjects are a 79 year-old man (Patient 1) with Myelodysplastic Syndrome (MDS), a 66 year-old woman (Patient 2) with Acute Myeloid Leukemia (AML), a 56 year-old man (Patient 3) with AML, and a 69 year-old man (Patient 4) with MDS. Patient 1 was initially misdiagnosed with neutropenic fever. Patient 2 was incidentally discovered to have erythematous skin lesions prior to initiating chemotherapy. Before starting second line chemotherapy, patient 3 developed pathergy at the site of a PICC line. Patient 4 developed erythema around a newly placed port before initiating chemotherapy. Only patients 1 and 3 received glucocorticoids. Patients 2, 3, and 4 were able to initiate chemotherapy without further complications.
LIMITATIONS
Heterogeneity of subjects in terms of prognostic factors, stage at diagnosis, and treatment strategies.
CONCLUSION
Early recognition and treatment of malignancy-associated Sweet's syndrome is imperative to limit patient morbidity and expeditiously provide anti-cancer treatments.
Collapse